ImmuPharma (IMM) Reaches New 1-Year High at $148.50
Shares of ImmuPharma PLC (LON:IMM) hit a new 52-week high during mid-day trading on Friday . The company traded as high as GBX 148.50 ($2.00) and last traded at GBX 144 ($1.94), with a volume of 479981 shares. The stock had previously closed at GBX 131.99 ($1.78).
A number of analysts have issued reports on IMM shares. Northland Securities reaffirmed a “buy” rating and set a GBX 181 ($2.44) price target on shares of ImmuPharma in a report on Thursday, September 21st. Northland Capital Partners reissued a “buy” rating and issued a GBX 181 ($2.44) target price on shares of ImmuPharma in a report on Thursday, September 21st.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/12/08/immupharma-imm-reaches-new-1-year-high-at-148-50.html.
ImmuPharma Company Profile
ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.
Receive News & Stock Ratings for ImmuPharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma PLC and related stocks with our FREE daily email newsletter.